PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD

Neurology

Volumn 55, Issue 2, 2000, Pages 205-209

  Kemppainen, N ^b   Ruottinen, H ^b   Nagren K ^b   Rinne, J O ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 5 (2,3 DIHYDROBENZOFURAN 7 YL) 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPIN 7 OL; CARBON 11; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; RACLOPRIDE;

ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MENTAL HEALTH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RATING SCALE;

EID: 0033854704     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.55.2.205     Document Type: Article

References (41)

1. Kaye J, May C, Daly E, et al. Cerebrospinal monoamine markers are decreased in dementia of Alzheimer's type with extrapyramidal signs. Neurology 1988;38:554-557.
2. Tabaton M, Schenone A, Romagnoli P, Mancardi GL. A quantitative and ultrastructural study of substantia nigra and nucleus centralis superior in Alzheimer's disease. Acta Neuropathol 1985;68:218-223.
3. Chui H, Mortimer J, Slager U, Bondareff W, Webster D. Pathologic correlates of dementia in Parkinson's disease. Arch Neurol 1986;43:991-995.
4. Mann DMA, Yates PO, Marcyniuk B. Dopaminergic neurotransmitter systems in Alzheimer's disease and in Down's syndrome at middle age. J Neurol Neurosurg Psychiatry 1987; 50:341-344.
5. 3H]GBR-12935 in Alzheimer's disease. Eur Neurol 1990;30:181-185.
6. Murray A, Weihmueller F, Marshall J, Hurtig H, Gottleib G, Joyce J. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann Neurol 1995;36:237-239.
7. Mizukawa K, McGeer EG, McGeer PL. Autoradiographic study on dopamine uptake sites and their correlation with dopamine levels and their striata from patients with Parkinson's disease, Alzheimer's disease and neurologically normal controls. Mol Chem Neuropathol 1993;18:133-144.
8. Lachowicz J, Sibley D. Molecular characteristics of mammalian dopamine receptors. Pharmacol Toxicol 1997;81:105-113.
9. Cross A, Crow T, Ferrier I, Johnson J, Markakis D. Striatal dopamine receptors in Alzheimer-type dementia. Neurosci Lett 1984;52:1-6.
10. Rinne JO, Säkö E, Paljärvi L, Mölsä P, Rinne UK. Brain dopamine D1 receptors in senile dementia. J Neurol Sci 1986; 73:219-230.
11. Rinne JO, Säkö E, Paljärvi L, Mölsä P, Rinne UK. Brain dopamine D2 receptors in senile dementia. J Neural Transm 1986;65:51-62.
12. Seeman P, Bzowej NH, Guan HC, et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases. Neuropsychopharmacology 1987;1:5-15.
13. Cortes R, Probst A, Palacios JM. Decreased densities of dopamine D1 receptors in the putamen and hippocampus in senile dementia of Alzheimer's type. Brain Res 1988;475:164-167.
14. Tyrrell P, Sawle G, Ibanez V, et al. Clinical and positron emission tomographic studies in the "extrapyramidal syndrome" of dementia of the Alzheimer type. Arch Neurol 1990; 47:1318-1323.
15. 11C]β-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology 1998;50:152-156.
16. 123I]IBZM. Neurology 1996;47:1065-1068.
17. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of consortium on DLB international workshop. Neurology 1996;47:1113-1124.
18. Halldin C, Farde L, Högberg T, et al. A comparative PET study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D2 receptor binding. Nucl Med Biol 1991;18:871-881.
19. 11C]raclopride. J Cereb Blood Flow Metab 1993; 13:310-314.
20. 11C]methyl triflate. Nucl Med Biol 1995;22:235-239.
21. Laihinen AO, Rinne JO, Ruottinen HM, et al. PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756. J Nucl Med 1994;35: 1916-1920.
22. 125I]iodosulpride, a highly selective ligand. Science 1985;228:752-754.
23. 3H]raclopride. J Neural Transm 1988;72:7-21.
24. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840.
25. 11C]NNC 756 as new radioligads for the D1-dopamine receptor. Psychopharmacol 1993;113:149-156.
26. 11C]NNC 756. Synapse 1999;32:93-109.
27. Reisine T, Yamamura H, Bird E, Spokes E, Enna S. Pre- and postsynaptic neurochemical alterations in Alzheimer's disease. Brain Res 1978;159:477-481.
28. Brooks D. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 1993;115:1-17.
29. Fazekas F, Alavi A, Chawluk JB, et al. Comparison of CT, MR and PET in Alzheimer's dementia and normal aging. J Nucl Med 1989;30:1607-1615.
30. Meltzer GC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 1996;47: 454-461.
31. Brun A, Gustafsson L. Distribution of cerebral degeneration in Alzheimer's disease. Arch Psychiatr Nervenkr 1976;22:15-33.
32. Creasy H, Schwartz M, Fredrickson H, et al. Quantitative computed tomography in dementia of the Alzheimer type. Neurology 1986;36:1563-1568.
33. Hubbard BM, Andersson JM. A quantitative study on cerebral atrophy in old age and senile dementia. J neurol Sci 1981;50: 135-145.
34. McGeer PL, Kamo H, Harrop R, et al. Positron emission and magnetic resonance imaging of suspected Alzheimer's disease patients. Can Med Assoc J 1986;134:597-607.
35. Rinne JO, Laihinen A, Någren K, et al. PET demonstrates different behaviour of striatal dopamine D1 and D2 receptors in early Parkinson's disease. J Neurosci Res 1990;27:494-499.
36. 11C]raclopride and PET. Ann Neurol 1992;31:184-192.
37. 11C]raclopride. J Neurol Sci 1995;132:156-161.
38. 11C]raclopride. Mov Disord 1992;7(suppl 1):141.
39. Duret M, Goldmen S, Messina D, Hildebrand J. Effect of L-dopa on dementia-related rigidity. Acta Neurol Scand 1989; 80:64-67.
40. Merello M, Sabe L, Teson A, et al. Extrapyramidalism in Alzheimer's disease: prevalence, psychiatric and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1994;57: 1503-1509.
41. Robertson HA. Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci 1992;15:201-206.